Objective: to compare treatment and survival of advanced prostate cancers between 1,476 non-Hispanic White and 531 Black men who were diagnosed with stage III or stage IV prostate cancer between 1998 and 2014 in the equal access Military Health System. Methods: The two racial groups were compared in receipt of treatment and overall survival using multivariable regression models. Results: Overall, there were no racial differences in receiving any treatment (aOR 0.95, 95% CI 0.72-1.26 for Black vs. White) or in receiving individual treatment type(s). Survival was similar for Black compared to White men (aHR 1.16, 95% CI 0.91-1.48). Conclusions: In the MHS, in general, there were no significant racial differences in treatment of advanced prostate cancer and survival, which might result from universal health care.
2.Identify any potential racial differences in receipt of surgery, radiation, hormone therapy, or chemotherapy for advanced prostate cancer or overall survival among non-Hispanic White and Black men with equal access to care.
3.Discuss reasons beyond access to care which may impact receipt of prostate cancer treatment(s) in an equal access healthcare setting.